Genvor Restores Trading Status and Expands Global Collaborative Research Network
Genvor (OTCID: GNVR) regained active OTCQB trading status on October 9, 2025, positioning the company to accelerate capital formation as it scales field trials and commercialization efforts.
The company said it now operates a newly opened laboratory in Woodland, California to support R&D for foliar and peptide-based formulations, and it is advancing four international research collaborations across Europe, Brazil, and the United States focused on peptide-based seed traits and foliar applications.
Management highlighted that these developments support product validation, global field trials, and expanded scientific capabilities for sustainable agriculture.
Genvor (OTCID: GNVR) ha riconquistato lo stato attivo di trading sull'OTCQB il 9 ottobre 2025, posizionando l'azienda per accelerare la formazione di capitale mentre espande i trial sul campo e le attività di commercializzazione.
L'azienda ha detto di gestire ora un laboratorio di recente apertura a Woodland, California per supportare R&D su formulazioni fogliari e a base di peptidi, e sta avanzando quattro collaborazioni internazionali di ricerca in Europa, Brasile e Stati Uniti, focalizzate su tratti di semi basati su peptidi e applicazioni foliar.
La direzione ha sottolineato che questi sviluppi supportano la validazione del prodotto, i trial globali sul campo e l'espansione delle capacità scientifiche per un'agricoltura sostenibile.
Genvor (OTCID: GNVR) recuperó el estado activo de trading en el OTCQB el 9 de octubre de 2025, posicionando a la empresa para acelerar la formación de capital a medida que escala los ensayos de campo y los esfuerzos de comercialización.
La compañía indicó que ahora opera un laboratorio recién abierto en Woodland, California para apoyar I+D de formulaciones foliares y basadas en péptidos, y está avanzando cuatro colaboraciones internacionales de investigación en Europa, Brasil y Estados Unidos, centradas en rasgos de semillas basados en péptidos y aplicaciones foliares.
La dirección destacó que estos desarrollos respaldan la validación de productos, ensayos globales en campo y la ampliación de las capacidades científicas para una agricultura sostenible.
Genvor (OTCID: GNVR)은 2025년 10월 9일에 OTCQB 거래 상태를 다시 활성화했고, 이를 통해 현장 시험 및 상용화 노력을 확대하는 자본 형성을 가속화할 수 있게 되었습니다.
회사는 이제 캘리포니아주 우드랜드에 새로 개설된 연구소를 운영하고 있다고 말했으며, R&D는 잎사귀(foliar) 및 펩타이드 기반 제형에 대한 연구를 지원하고, 유럽, 브라질, 미국 전역에서 펩타이드 기반 종자 형질 및 잎사귀 적용에 중점을 둔 네 가지 국제 연구 협력을 진행 중입니다.
경영진은 이러한 개발이 제품 검증, 글로벌 현장 시험 및 지속 가능한 농업을 위한 과학적 역량 확대를 지원한다고 강조했습니다.
Genvor (OTCID: GNVR) a retrouvé son statut actif de négociation OTCQB le 9 octobre 2025, ce qui permet à l'entreprise d'accélérer la collecte de capital pendant qu'elle intensifie ses essais sur le terrain et ses efforts de commercialisation.
L'entreprise a indiqué qu'elle exploite désormais un laboratoire récemment ouvert à Woodland, Californie pour soutenir la R&D sur des formulations foliaires et à base de peptides, et qu'elle fait progresser quatre collaborations internationales en recherche à travers l'Europe, le Brésil et les États-Unis, axées sur des traits de semences à base de peptides et des applications foliaires.
La direction a souligné que ces développements soutiennent la validation des produits, les essais globaux sur le terrain et l'élargissement des capacités scientifiques pour une agriculture durable.
Genvor (OTCID: GNVR) hat am 9. Oktober 2025 seinen aktiven OTCQB-Handelsstatus wiedererlangt, was das Unternehmen in die Lage versetzt, die Kapitalbeschaffung zu beschleunigen, während es Feldversuche skaliert und Bestrebungen zur Kommerzialisierung vorantreibt.
Das Unternehmen teilte mit, dass nun ein neu eröffnetes Labor in Woodland, Kalifornien betrieben werde, um F&E für foliar- und peptidbasierte Formulierungen zu unterstützen, und es schreitet voran mit vier internationalen Forschungskooperationen in Europa, Brasilien und den USA, die sich auf peptidbasierte Saatgutmerkmale und Blattapplikationen konzentrieren.
Das Management hob hervor, dass diese Entwicklungen die Produktvalidierung, globale Feldversuche und erweiterte wissenschaftliche Fähigkeiten für eine nachhaltige Landwirtschaft unterstützen.
Genvor (OTCID: GNVR) استعاد وضعه النشط في تداول OTCQB في 9 أكتوبر 2025، مما يمكّن الشركة من تسريع جمع رأس المال مع توسعها في تجارب الحقل وجهودها في التسويق.
قالت الشركة إنها تدير الآن مختبراً افتُتح حديثاً في وودلاند، كاليفورنيا لدعم البحث والتطوير في التركيبات الورقية والمركّبات القائمة على الببتيدات، وهي تتقدم في أربع تعاونات بحثية دولية عبر أوروبا والبرازيل والولايات المتحدة تركز على سمات البذور القائمة على الببتيدات وتطبيقات ورقية.
وأبرزت الإدارة أن هذه التطورات تدعم التحقق من المنتج، والتجارب الميدانية العالمية، وتوسيع القدرات العلمية للزراعة المستدامة.
Genvor (OTCID: GNVR) 于2025年10月9日重新获得 OTCQB交易资格，使公司能够在扩大现场试验和商业化工作时加速资本形成。
公司表示现已在加利福尼亚州伍德兰新开设的实验室开展，支持用于叶面喷施与基于肽的配方的研发，并且正在推进跨欧洲、巴西和美国的 四项国际研究合作，聚焦于基于肽的种子性状与叶面应用。
管理层强调，这些进展将支持产品验证、全球现场试验以及扩大在可持续农业方面的科学能力。
- OTCQB trading status restored on Oct 9, 2025
- Opened and staffed Woodland, California R&D laboratory
- Advancing 4 R&D collaborations across Europe, Brazil, and the United States
- Progressing multiple peptide applications including seed traits and foliar formulations
- No financial terms, fundraising size, or timetable for capital formation disclosed
- No quantified commercialization timeline or revenue guidance provided
Woodland, CA, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Genvor, Inc. (OTCID: GNVR), a pioneer in AI-accelerated peptide technology for sustainable agriculture, today announced that it has regained active OTCQB trading status on OTC Markets, positioning the company to accelerate capital formation as it scales field trials across multiple continents and crop applications. The reinstatement reflects the company’s ongoing commitment to compliance, transparency, and long-term growth as it advances four active research and development collaborations spanning three continents.
“Restoring OTCID trading status marks an important milestone in Genvor’s progression,” said CEO, Chad Pawlak. “With our new California laboratory operational and four international collaborations advancing through field trials, we are building meaningful global collaborations and expanding our scientific capabilities to deliver tangible innovation in sustainable agriculture.”
Genvor is actively collaborating with four research and development projects in Europe, Brazil, and the United States. These collaborations focus on advancing peptide-based formulations and sustainable crop protection to enhance resilience and performance under diverse field conditions. The company is trialing multiple applications of its peptides including seed traits and various foliar formulations.
The company recently opened and staffed a laboratory in Woodland, California, which supports R&D for foliar and peptide-based formulations. The lab complements Genvor’s ongoing international field programs and development efforts.
Genvor is building momentum through new and ongoing collaborations that support product validation and future commercialization. The company invites forward-thinking partners and investors to join its mission of developing science-based, sustainable technologies that improve agricultural performance and environmental outcomes.
About Genvor
Genvor (OTCQB: GNVR) is pioneering the future of sustainable agriculture through its proprietary AI-accelerated peptide design platform that transforms single discoveries into multi-crop protection and optimization opportunities across diverse agricultural environments. The company’s proprietary BioCypher Algorithm combines computational biology, machine learning, and regulatory benchmarks to create peptides that optimize agricultural outcomes with biological safety. With 2 issued U.S. patents covering antimicrobial and nutrient-enhancing peptides and 24 proprietary peptides in active development, Genvor offers ready-to-deploy licensing opportunities that integrate with existing production infrastructure and regulatory frameworks. For more information, visit www.genvor.com.
Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties. Actual results may differ materially from those expressed or implied. Genvor undertakes no obligation to update forward-looking statements except as required by applicable law.
Contacts:
Investor Relations
Genvor Incorporated
Marketing@genvor.com
www.genvor.com
Media
Carly Scaduto
carly@carlyscadutoconsulting.com
FAQ
What does Genvor's restored OTCQB status mean for GNVR shareholders?
Where is Genvor's new laboratory located and what does it support for GNVR?
How many and where are Genvor's international collaborations for GNVR?
What peptide applications is Genvor trialing under GNVR?
Does Genvor disclose funding amounts or a commercialization timeline for GNVR?
